



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Antoni TORRENS JOVER, et al.

SERIAL NO: 10/566,399

GAU: 1614

FILED: September 26, 2006

EXAMINER:

FOR: 2'-4-(HYDROXYMETHYL-PHENYLAMINO)-PIPERIDINE-1-YL-N-(9H-CARBAZOL-3-YL)-ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATMENT OF OBESITY

### INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

#### REFERENCES

- The applicant(s) wish to make of record the reference(s) listed on the attached form PTO-1449. Copies of the listed reference(s) are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language reference(s).
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

#### RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

#### CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

#### DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

Paul J. Killos  
Registration No. 58,014

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Docket No. 284394US0PCT

AUG 27 2007



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Antoni TORRENS JOVER, et al.

SERIAL NO: 10/566,399

GAU: 1614

FILED: September 26, 2006

EXAMINER:

FOR: 2'-4-(HYDROXYMETHYL-PHENYLAMINO)-PIPERIDINE-1-YL-N-(9H-CARBAZOL-3-YL)-ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATMENT OF OBESITY

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- The applicant(s) wish to make of record the reference(s) listed on the attached form PTO-1449. Copies of the listed reference(s) are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language reference(s).
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**


- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon



Paul J. Killos  
Registration No. 58,014

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

AUG 27 2007

Page 1 of 1

DOCKET NO.: 284394US0PCT



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF:

Antoni TORRENS JOVER, et al.

SERIAL NO: 10/566,399

GROUP: 1614


FILED: September 26, 2006

EXAMINER:

FOR: 2'-4-(HYDROXYMETHYL-PHENYLAMINO) -PIPERIDINE-1-YL!-N- (9H-CARBAZOL-3-YL) - ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATMENT OF OBESITY

**STATEMENT OF RELEVANCY**

All the References mentioned on PTO Form 1449 are discussed in the Application Text



SHEET 1 OF 2

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 284394US0PCT	PATENT & TRADEMARK OFFICE		SERIAL NO. 10/566,399
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Antoni TORRENS JOVER, et al.					
		FILING DATE September 26, 2006			GROUP 1614		
		U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AJ				YES	NO	
	AK						
	AL						
	AM						
	AN						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AO	Kazuhiko TATEMOTO, et al. "NEUROPEPTIDE Y-A NOVEL BRAIN PEPTIDE WITH STRUCTURAL SIMILARITIES TO PEPTIDE YY AND PANCREATIC POLYPEPTIDE", NATURE, Vol. 296, April 15, 1982, Pages 659-660					
	AP	James F. FLOOD, et al. "MODULATION OF MEMORY PROCESSING BY NEUROPEPTIDE Y", BRAIN RESEARCH, Vol. 421, 1987, Pages 280-290					
	AQ	John P. REDROBE, et al. "MULTIPLE RECEPTORS FOR NEUROPEPTIDE Y IN THE HIPPOCAMPUS: PUTATIVE ROLES IN SEIZURES AND COGNITION", BRAIN RESEARCH, Vol. 848, 1999, Pages 153-166					
	AR	Markus HEILIG, et al. "ANXIOLYTIC-LIKE EFFECT OF NEUROPEPTIDE Y (NPY), BUT NOT OTHER PEPTIDES IN AN OPERANT CONFLICT TEST", REGULATORY PEPTIDES, Vol. 41, 1992, Pages 61-69					
	AS	Martin C. MICHEL, et al. "NEUROPEPTIDE Y: A POSSIBLE ROLE IN HYPERTENSION?", JOURNAL OF HYPERTENSION, Vol. 13, No. 4, 1995, Pages 385-395					
	AT	Donald R. GEHLERT, "SUBTYPES OF RECEPTORS FOR NEUROPEPTIDE Y: IMPLICATIONS FOR THE TARGETING OF THERAPEUTICS", LIFE SCIENCES, Vol. 55, No. 8, 1994, Pages 551-562					
	AU	Philip HIPSkind, et al. "NEUROPEPTIDE Y: AT THE DAWN OF SUBTYPE SELECTIVE ANTAGONISTS", ANNUAL REPORTS ON MEDICINAL CHEMISTRY, Vol. 31 Pages 1-10					
	AV	Lars GRUNDEMAR, et al. "NEUROPEPTIDE Y EFFECTOR SYSTEMS: PERSPECTIVES FOR DRUG DEVELOPMENT", TIPS REVIEWS, Vol. 15, May 1994, Pages 153-159					
	AW	Yinghe HU, et al. "IDENTIFICATION OF A NOVEL HYPOTHALAMIC NEUROPEPTIDE Y RECEPTOR ASSOCIATED WITH FEEDING BEHAVIOR", THE JOURNAL OF BIOMEDICAL CHEMISTRY, Vol. 271, No. 42, October 18, 1996, Pages 26315-26319					
	AX	Nigel R. LEVENS, et al. "NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS AS ANTI-OBESITY DRUGS", CURRENT OPINION IN INVESTIGATIONAL DRUGS, Vol. 4, No. 10, 2003, Pages 1198-1204			<input checked="" type="checkbox"/> Additional References sheet(s) attached		
Examiner				Date Considered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)  LIST OF REFERENCES CITED BY APPLICANT		ATTY DOCKET NO. 284394US0PCT	SERIAL NO. 10/566,399
		APPLICANT Antoni TORRENS JOVER, et al.	
		FILING DATE September 26, 2006	GROUP 1614
		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)	
AY	Andrew V. TURNBULL, et al. "SELECTIVE ANTAGONISM OF THE NPY Y5 RECEPTOR DOES NOT HAVE A MAJOR EFFECT ON FEEDING IN RATS", DIABETES, Vol. 51, August 2002, Pages 2441-2449		
AZ	O. DELLA-ZUANA, et al. "A POTENT AND SELECTIVE NPY Y <sub>5</sub> ANTAGONIST REDUCES FOOD INTAKE BUT NOT THROUGH BLOCKADE OF THE NPY Y <sub>5</sub> RECEPTOR", INTERNATIONAL JOURNAL OF OBESITY, Vol. 28, 2004, Pages 628-639		
AAA	Povl KROGSGAARD LARSEN, et al. "A TEXTBOOK OF DRUG DESIGN AND DEVELOPMENT", Pages 630-643		
AAB	J.F.W. MCOMIE, "PROTECTIVE GROUPS IN ORGANIC CHEMISTRY", 1973, 15 pages		
AAC	Theodora W. GREENE, et al. "PROTECTIVE GROUPS IN ORGANIC SYNTHESIS" 1991, 3 pages		
AAD	M.E. AULTON, "THE SCIENCE OF DOSAGE FORMS", PHARMACEUTICS, 2 <sup>nd</sup> EDITION, 2002, pages		
AAE	James SWARBRICK, et al. "THE ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY", 2 <sup>nd</sup> EDITION, 2002, two pages and pages xvii-xxi		
AAF	Gilbert S. BANKER, et al. "MODERN PHARMACEUTICS", DRUGS AND PHARMACEUTICAL SCIENCES, Vol. 121, 4 <sup>th</sup> EDITION, 2002, 2 pages		
AAG	Leon LACHMAN, et al. "THE THEORY AND PRACTICE OF INDUSTRIAL PHARMACY", 3 <sup>rd</sup> EDITION, 1986, 2 pages		
AAH	Michael RATHBONE, et al. "MODIFIED-RELEASE DRUG DELIVERY TECHNOLOGY", DRUGS AND THE PHARMACEUTICAL SCIENCES, Vol. 126, 2002, 9 pages		
AAI	Stephen D. BRUCK, "CONTROLLED DRUG DELIVERY", BASIC CONCEPTS, Vol. 1, 1983, 3 pages		
AAJ	Kanji TAKADA, et al. "ORAL DRUG DELIVERY, TRADITIONAL", 1999, Pages 728-742		
AAK	Joseph FIX, "ORAL DRUG DELIVERY, SMALL INTESTINE AND COLON", 1999 Pages 698-728		
AAL			
AAM			
AAN			
AAO			
Examiner		Date Considered	

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.